Please login to the form below

Not currently logged in
Email:
Password:

Brineura

This page shows the latest Brineura news and features for those working in and with pharma, biotech and healthcare.

Orphan drugs dominate UK Prix Galien shortlist, medtech debuts

Orphan drugs dominate UK Prix Galien shortlist, medtech debuts

Seven companies have been shortlisted for the Orphan Product Award; Amicus (Galafold), Biogen (Spinraza), Biomarin (Brineura), Eusa (Qarziba), Intercept (Ocaliva), Kyowa Kirin (Crysvita) and Shire (Revestive).

Latest news

  • CHMP backs two rare disease therapies at April meeting CHMP backs two rare disease therapies at April meeting

    Biogen's Spinraza and BioMarin's Brineura near EU approval. Two new drugs for rare diseases from Biogen and BioMarin headed the list of new therapies backed by the EMA's ... The importance of Brineura to the company has gained prominence after it was

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Nektar Therapeutics appoints Jeff Ajer Nektar Therapeutics appoints Jeff Ajer

    officer. There he worked on establishing BioMarin’s global footprint and commercial infrastructure and has played a leadership role in the launches and growth strategies for brands including Brineura, Vimizim, Kuvan

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics